Emmaus Life Sciences, Inc. (EMMA)
| Market Cap | 64.47M |
| Revenue (ttm) | 7.46M |
| Net Income (ttm) | -32.89M |
| Shares Out | 46.02M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.33 |
| Previous Close | $1.23 |
| Change ($) | 0.10 |
| Change (%) | 8.13% |
| Day's Open | 1.40 |
| Day's Range | 1.33 - 1.40 |
| Day's Volume | 2,333 |
| 52-Week Range | 0.702 - 2.16 |
--Meeting Will be Open to the Public-- --Meeting Will be Open to the Public--
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to t...
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to t...
--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in ...
TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the ...
TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EM...
TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in...
TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, is pleased to announce that it has engaged Partner ...
TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously i...
TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the...
Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indi...
Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.
About EMMA
Emmaus Life Sciences engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases.... [Read more...]
| Industry Biotechnology | Founded 2000 |
| CEO George Carpenter | Employees 28 |
| Stock Exchange OTCMKTS | Ticker Symbol EMMA |
Financial Performance
In 2018, EMMA's revenue was $1.32 million, an increase of 923.74% compared to the previous year's $128,500. Losses were -$9.60 million, 34.9% more than in 2017.